BiondVax Pharmaceuticals recently announced that it passed an intensive two-day QP GMP audit – giving it a green light to advance clinical development of its universal flu vaccine, M-001, in the EU. This demanding certification is a requirement for companies intending to manufacture a clinical grade product for human trials anywhere in Europe.In case you're wondering, they're located in Nes Ziona, which is inside the 1949 armistice lines. I wonder how many Euromorons will choose to get the flu anyway rather than using a product from an Israeli company. Heh.
BiondVax, an innovative biopharmaceutical company developing a flu vaccine designed to provide multi-season and multi-strain protection against most human influenza virus strains, also announced that it will conduct collaborative studies with MonoSol Rx located in New Jersey, to investigate the activity of M-001 when formulated utilizing MonoSol’s technology for administration by mouth.
Labels: Israeli high tech